Binocular Visual Rehabilitation in Paralytic Strabismus by Botulinum A Toxin Chemodenervation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the effect of botulinum A toxin (BTXA) chemodenervation in paralytic strabismus patients withoutsurgical correction. Methods: A retrospective chart review of 51 patients who were diagnosed as paralytic strabismus and underwent BTXA chemodenervationwas performed. The patients were divided into four groups according to the cause of paralytic strabismus ofvasculopathy, neoplasm, trauma, and idiopathic. They were also divided into two groups of early and late treatment accordingto the initiation time of BTXA chemodenervation after the onset of strabismus (3 months), and of the initial strabismustype of exotropia and esotropia. We investigated the changes of angle of deviation and diplopia after BTXA chemodenervation. Results: The average deviation of angles decreased by 25.2 prism diopter (PD) (35.1 to 9.9 PD) in total patients, and the overallsuccess rate was 64.7% (33 by 51), and the there was no statistically significant difference in success rate between eachgroup divided by the cause of paralytic strabismus. According to the treatment timing, the deviation of the angle decreasedby 28.0 PD (36.8 to 8.8 PD) in the early treatment group, and 21.3 PD (33.5 to 12.2 PD) in late treatment group at the time ofthe last postinjective follow-up. According to the initial strabismus type, the average angle of deviation decreased by 20.3 PD(35.6 to 15.3 PD) in exotropia group by cranial nerve 3 palsy, and 24.4 PD (32.5 to 8.1 PD) in esotropia by cranial nerve 6 palsy. Conclusions: BTXA chemodenervation reduced the angle of deviation and the number of patients with diplopia regardless ofthe cause of paralytic strabismus. Early BTXA chemodenervation can be considered as the first treatment of choice in paralyticstrabismus, especially in esotropia patients.
Abstract
Purpose: To investigate the effect of botulinum A toxin (BTXA) chemodenervation in paralytic strabismus patients withoutsurgical correction. Methods: A retrospective chart review of 51 patients who were diagnosed as paralytic strabismus and underwent BTXA chemodenervationwas performed. The patients were divided into four groups according to the cause of paralytic strabismus ofvasculopathy, neoplasm, trauma, and idiopathic. They were also divided into two groups of early and late treatment accordingto the initiation time of BTXA chemodenervation after the onset of strabismus (3 months), and of the initial strabismustype of exotropia and esotropia. We investigated the changes of angle of deviation and diplopia after BTXA chemodenervation. Results: The average deviation of angles decreased by 25.2 prism diopter (PD) (35.1 to 9.9 PD) in total patients, and the overallsuccess rate was 64.7% (33 by 51), and the there was no statistically significant difference in success rate between eachgroup divided by the cause of paralytic strabismus. According to the treatment timing, the deviation of the angle decreasedby 28.0 PD (36.8 to 8.8 PD) in the early treatment group, and 21.3 PD (33.5 to 12.2 PD) in late treatment group at the time ofthe last postinjective follow-up. According to the initial strabismus type, the average angle of deviation decreased by 20.3 PD(35.6 to 15.3 PD) in exotropia group by cranial nerve 3 palsy, and 24.4 PD (32.5 to 8.1 PD) in esotropia by cranial nerve 6 palsy. Conclusions: BTXA chemodenervation reduced the angle of deviation and the number of patients with diplopia regardless ofthe cause of paralytic strabismus. Early BTXA chemodenervation can be considered as the first treatment of choice in paralyticstrabismus, especially in esotropia patients.
참고문헌 (15)
- de Camargo GB, "Paralytic strabismus : review of 24 years at"Santa Casa de Sao Paulo"", Arq Bras Oftalmol, 70, pp.585~587 (2007)
- Richards BW, "Causes and prognosis in 4,278 cases of paralysis of the oculomotor, trochlear, and abducens cranial nerves", Am J Ophthalmol, 113, pp.489~496 (1992)
- Berlit P, "Isolated and combined pareses of cranial nerves III, IV and VI. A retrospective study of 412 patients", J Neurol Sci, 103, pp.10~15 (1991)
- Scott AB, "Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery", Ophthalmology, 87, pp.1044~1049 (1980)
- Gomez de Liano R, "The use of botulinum toxin in strabismus treatment", J Binocul Vis Ocul Motil, 69, pp.51~60 (2019)
- Rush JA, "Paralysis of cranial nerves III, IV, and VI. Cause and prognosis in 1,000 cases", Arch Ophthalmol, 99, pp.76~79 (1981)
- Lee WY, "A clinical study of paralytic strabismus", J Korean Ophthalmol Soc, 34, pp.549~554 (1993)
- 박운철, "후천성 3, 4, 6번 뇌신경마비의 임상 양상과 자연 경과", 대한안과학회지, 46(9), pp.1555~1562 (2005), 대한안과학회
- Repka MX, "The efficacy of botulinum neurotoxin A for the treatment of complete and partially recovered chronic sixth nerve palsy", J Pediatr Ophthalmol Strabismus, 31, pp.79~83 (1994)
- Han SH, "The effect of botulinum toxin chemodenervation in chronic paralytic strabismus", J Korean Ophthalmol Soc, 41, pp.751~757 (2000)
- Stanley EF, "Botulinum toxin blocks quantal but not non-quantal release of ACh at the neuromuscular junction", Brain Res, 261, pp.172~175 (1983)
- Metz HS, "Botulinum toxin treatment of acute sixth and third nerve palsy", Graefes Arch Clin Exp Ophthalmol, 226, pp.141~144 (1988)
- Kowal L, "Botulinum toxin in the treatment of strabismus. A review of its use and effects", Disabil Rehabil, 29, pp.1823~1831 (2007)
- Dawson EL, "The role of botulinum toxin A in acute-onset esotropia", Ophthalmology, 106, pp.1727~1730 (1999)
- Pamphlett R, "Early terminal and nodal sprouting of motor axons after botulinum toxin", J Neurol Sci, 92, pp.181~192 (1989)